



## **Synlogic to Webcast Presentation at the Leerink Partners Roundtable Series: Rare Disease & Oncology**

September 25, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 25, 2018-- Synlogic([Nasdaq:SYBX](https://www.nasdaq.com/symbol/sybx)) announced today that Aoife Brennan, M.B., B.Ch., Synlogic's interim president and chief executive officer, and chief medical officer, will present a corporate update at the Leerink Partners Roundtable Series on Rare Diseases and Oncology at 11:30 am ET on Tuesday, October 2, 2018, in New York City.

A live webcast of the presentation can be accessed under "[Event Calendar](#)" in the Investors & Media section of the Company's website. An archived webcast recording will be available on the Synlogic website for approximately 30 days after the event.

### **About Synlogic**

Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform. Synlogic leverages the tools and principles of synthetic biology to genetically engineer probiotic microbes to perform or deliver critical functions missing or damaged due to disease. The company's two lead programs, SYN1020 and SYN1618, target hyperammonemia as a result of liver damage or genetic disease, and PKU, respectively. When delivered orally, Synthetic Biotic medicines can act from the gut to compensate for the dysfunctional metabolic pathway and have a systemic effect, with the potential to significantly improve symptoms of disease for affected patients. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of more common diseases, including liver disease, inflammatory and immune disorders, and cancer. Synlogic is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease (IBD). For more information, please visit [www.synlogictx.com](http://www.synlogictx.com).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180925006153/en/>

Source: Synlogic

### **Synlogic**

#### **MEDIA CONTACT:**

Courtney Heath, 617-872-2462

[courtney@scientpr.com](mailto:courtney@scientpr.com)

or

#### **INVESTOR CONTACT:**

Elizabeth Wolffe, Ph.D., 617-207-5509

[liz@synlogictx.com](mailto:liz@synlogictx.com)